Form 13-F position report

RECURSION PHARMACEUTICALS INC

Reported by ALLIANCEBERNSTEIN L P

RXRX CUSIP 75629V104 Manager CIK 0001109448

Reported 361,374 shares, up 108,860 (43.1%) from the prior quarter.

Reported value 36.9%; share count 43.1% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q2 2025
Shares 361,374 Quarter-end amount reported
Reported value $1,828,552 Fair value at quarter end
Consecutive quarters held 17 Through Q2 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 49263000
2022-03-31 24206000
2022-06-30 29312000
2022-09-30 34445000
2022-12-31 3011565
2023-03-31 2058776
2023-06-30 2305705
2023-09-30 1247883
2023-12-31 2079632
2024-03-31 1436119
2024-06-30 1629705
2024-09-30 1431967
2024-12-31 1644127
2025-03-31 1335799
2025-06-30 1828552
2025-09-30 1765984
2025-12-31 1478020
2026-03-31 1871191
2026-06-30 1449912
2026-09-30 1878671

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for RECURSION PHARMACEUTICALS INC held by ALLIANCEBERNSTEIN L P.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 454,884 -17,400 (-3.7%) < 0.01% $1,878,671 2026-11-16
Q2 2026 Added 472,284 +14,780 (3.2%) < 0.01% $1,449,912 2026-08-14
Q1 2026 Added 457,504 +96,130 (26.6%) < 0.01% $1,871,191 2026-05-15
Q4 2025 Reduced 361,374 -508 (-0.1%) < 0.01% $1,478,020 2026-02-17
Q3 2025 Added 361,882 +508 (0.1%) < 0.01% $1,765,984 2025-11-14
Q2 2025 Added 361,374 +108,860 (43.1%) < 0.01% $1,828,552 2025-08-14
Q1 2025 Added 252,514 +9,300 (3.8%) < 0.01% $1,335,799 2025-05-15
Q4 2024 Added 243,214 +25,920 (11.9%) < 0.01% $1,644,127 2025-02-12
Q3 2024 Unchanged 217,294 0 (0.0%) < 0.01% $1,431,967 2024-11-14
Q2 2024 Added 217,294 +73,250 (50.9%) < 0.01% $1,629,705 2024-08-14
Q1 2024 Reduced 144,044 -66,872 (-31.7%) < 0.01% $1,436,119 2024-05-14
Q4 2023 Added 210,916 +47,794 (29.3%) < 0.01% $2,079,632 2024-02-14
Q3 2023 Reduced 163,122 -145,540 (-47.2%) < 0.01% $1,247,883 2023-11-14
Q2 2023 Unchanged 308,662 0 (0.0%) < 0.01% $2,305,705 2023-08-15
Q1 2023 Reduced 308,662 -81,943 (-21.0%) < 0.01% $2,058,776 2023-05-15
Q4 2022 Reduced 390,605 -2,846,739 (-87.9%) < 0.01% $3,011,565 2023-02-15
Q3 2022 Reduced 3,237,344 -363,616 (-10.1%) 0.02% $34,445,000 2022-11-15
Q2 2022 Added 3,600,960 +220,242 (6.5%) 0.01% $29,312,000 2022-08-15
Q1 2022 Added 3,380,718 +504,899 (17.6%) < 0.01% $24,206,000 2022-05-13
Q4 2021 Added 2,875,819 +1,236,478 (75.4%) 0.02% $49,263,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

398 managers reported RECURSION PHARMACEUTICALS INC for Q2 2025.

Managers reporting RECURSION PHARMACEUTICALS INC in Q2 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
VANGUARD GROUP INC Added 36,071,178 +3,783,201 < 0.01% $182,520,161 17 qtrs
ARK Investment Management LLC Reduced 32,988,631 -1,826,871 1.22% $166,922,471 17 qtrs
BlackRock Inc Added 28,371,063 +4,864,474 < 0.01% $143,557,577 4 qtrs
BAILLIE GIFFORD & CO Reduced 24,173,815 -219,200 0.09% $122,319,504 17 qtrs
SOFTBANK GROUP CORP Unchanged 14,667,491 0 0.3% $74,217,504 3 qtrs
Kinnevik AB publ Unchanged 13,434,171 0 100.0% $67,976,906 11 qtrs
Mubadala Investment Co PJSC Unchanged 12,985,927 0 0.35% $65,708,791 7 qtrs
STATE STREET CORPORATION Reduced 11,179,539 -1,905,719 < 0.01% $56,568,467 17 qtrs
Novo Holdings A S Unchanged 9,665,128 0 3.45% $48,905,548 3 qtrs
MIC Capital Management UK LLP Unchanged 9,644,032 0 9.58% $48,798,807 15 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2025
Filed
August 14, 2025
Filing type
13F-HR
Position type
CL A

Voting authority reported

Sole
361,374
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.